Cutera

Cutera, Inc. engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cutera reports strong 2022 performance with focus on AviClear growth

Cutera's performance in 2022 showcased resilience and growth potential, driven by the successful AviClear launch. While facing revenue challenges in Q4 2022, the company is optimistic about achieving cash flow breakeven by Q4 2023. With a bullish outlook for 2023, Cutera aims to leverage its core business strength and accelerate AviClear sales.

Cutera reports Q1 revenue dip, focuses on AviClear growth

Cutera faces challenges in North American sales but sees growth opportunities internationally and with AviClear devices.
Financials show a loss in adjusted EBITDA and decreased cash, but the company is focused on improving execution and driving utilization rates.
Retention incentives have been effective, and steps are being taken to enhance performance and return to sustainable growth.

Cutera reports Q2 revenue decline, focuses on AviClear performance

Cutera reported Q2 2023 revenue of $61.2 million, down 5% YoY, with an adjusted EBITDA loss of $11.6 million. The company is focusing on AviClear performance, quality control, and core business growth.
Challenges include declining core capital business, operational issues, and macroeconomic challenges. Opportunities lie in optimizing AviClear utilization, enhancing reliability, and introducing new products for growth.
Cutera's commitment to addressing challenges, enhancing service levels, and executing a strategic plan for sustainable growth is evident. The organization is resilient in the face of macroeconomic pressures and is adapting its strategies for success.
Retention bonuses, successful employee retention, and efforts to improve quality control measures demonstrate Cutera's internal strengths. The company's strategic approach to product lines and growth showcases a positive outlook for the future.

Cutera reports Q3 revenue decline, focuses on cost reduction

Cutera faces revenue decline and operational challenges in Q3 2023, impacting full-year guidance. Plans for cost reduction, growth strategies, and personnel restructuring in progress. Positive outlook for achieving financial goals with confidence.

Cutera reports Q4 revenue growth, focuses on AviClear expansion

Cutera's Q4 performance reflects resilience with better-than-anticipated revenue and stable AviClear revenue.
Focus on operational excellence, global franchise building, and customer support positions Cutera for long-term success.
Efforts to address challenges like inventory management and customer adoption of new business models are crucial for growth.

Cutera reports mixed Q1 results, focuses on AviClear growth

Cutera's Q1 performance showed a revenue decline but growth in AviClear revenue, with a focus on operational excellence and building a strong AviClear franchise. The company faces challenges with declining customer site volumes and an uncertain timeline for patient demand. However, opportunities exist in international expansion, R&D innovation, and addressing future market needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc.

Cutera Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-K

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR) a leading provider of aesthetic and dermatology solutions, is proud to reveal the refreshed truBody brand. This award-winning treatment pairs two clinically proven technologies for a customized, convenient, and complete approach to fat reduction and muscle toning with 15-minute treatment options.

Cutera® Unveils the Reimagined truBody® Brand

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cutera, Inc. (“Cutera” or the “Company”) (NASDAQ: CUTR) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2023, Cutera announced that it was unable to timely file its 2022 Annual Report.

The Law Offices of Frank R. Cruz Announces Investigation of Cutera, Inc. (CUTR) on Behalf of Investors

Cutera, Inc. (NASDAQ:CUTR ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Dave Mowry - Chief Executive Officer Rohan Seth - Chief Financial Officer Conference Call Participants Jon Block - Stifel Margaret Kaczor - William Blair Sim Kaur - Piper Sandler George Sellers - Stephens Inc. Anthony Vendetti - Maxim Group Operator Thank you for standing by. This is the conference operator.

Cutera, Inc. (CUTR) Q4 2022 Earnings Call Transcript

Cutera (CUTR) delivered earnings and revenue surprises of 62.07% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cutera (CUTR) Reports Q4 Loss, Misses Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 Financial and Operational Highlights Consolidated revenue of $67.4 million driven by AviClear treatment revenue and strength in Skincare, an increase of 3% as reported and 10% in constant currency from the prior-year period.

Cutera Announces Fourth Quarter and Full-Year 2022 Financial Results along with 2023 Outlook

Cutera (CUTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cutera (CUTR) Expected to Beat Earnings Estimates: Should You Buy?

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year of 2022 after the market close on Tuesday, February 28, 2023. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day.

Cutera, Inc. to Announce Fourth Quarter and Full-Year 2022 Results on February 28, 2023

Cutera (CUTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Cutera (CUTR): Can Its 12.5% Jump Turn into More Strength?

Baxter

Tricida Inc

Third Harmonic Bio Inc

Vera Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)

Cutera (CUTR) now expects revenues to be in the range of $252-$253 million against previously guided revenue range of $255-$260 million for 2022.

Cutera (CUTR) Announces Preliminary Full-Year 2022 Results

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. These results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit.

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2022

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced the pricing of $100 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cutera also granted the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes. The sale of the notes is expected to close on December 12, 2022, subject to customary closing conditions.

Cutera, Inc. Announces Pricing of Offering of $100 Million of Convertible Senior Notes

BRISBANE, Calif--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cutera also intends to grant the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes.

Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today disclosed that it has provided a response to a recent FDA inquiry.

Cutera, Inc. Provides Response to FDA Inquiry

Cutera's revenue growth heavily compressed by FX headwinds, resulting in a c.6 percentage point headwind. AviClear revenue growth was the key standout, with >160 devices now in the installed base.

Cutera: AviClear Key Differentiator, Reaffirm Buy

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference at 2:00 pm ET on Wednesday, November 30, 2022, at the Lotte New York Palace Hotel, New York, NY.

Cutera, Inc. to Participate in a Fireside Chat at the 34th Annual Piper Sandler Healthcare Conference

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Stephens Annual Investment Conference at 4:00 pm CT on Wednesday, November 16, 2022, at the Grand Hyatt Hotel, Nashville, TN.

Cutera, Inc. to Participate in a Fireside Chat at the Stephens Annual Investment Conference

BRISBANE, Calif.--( BUSINESS WIRE )--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and J. Daniel Plants, Executive Chairperson, will participate in a fireside chat at the Stifel Healthcare Conference at 8:00 am ET on Tuesday, November 15, 2022, at the Lotte New York Palace Hotel, New York, NY.

Cutera, Inc. to Participate in a Fireside Chat at the Stifel Healthcare 2022 Conference

AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Cutera, Inc. (NASDAQ:CUTR ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants David Mowry - CEO Rohan Seth - CFO Conference Call Participants Jonathan Block - Stifel George Sellers - Stephens Inc. Operator Thank you for standing by. This is the conference operator.

Cutera, Inc. (CUTR) Q3 2022 Earnings Call Transcript

Cutera (CUTR) delivered earnings and revenue surprises of 20% and 0.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Cutera Stock (CUTR)